Q-omics provides the consensus-scored PIMREG profile across patient tissues and cancer cell-line models. PIMREG expression is associated with patient survival in 33 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PIMREG is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PIMREG RNA expression shows 27,481 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, BLCA, and LUAD as cancer lineages where PIMREG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIMREG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIMREG survival associations across molecular data types. PIMREG RNA expression shows survival associations in the most cancer types (33), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIMREG RNA expression–survival associations across cancer types. High PIMREG expression shows unfavorable associations in MESO, KIRP, KIRC, ACC, KICH and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PIMREG RNA expression.
This table summarizes PIMREG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PIMREG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIMREG shows higher tumor expression in BLCA, HNSC, LUAD, KIRP, KIRC and COAD. The BLCA box plot shows higher PIMREG RNA expression in tumor versus normal tissue (log2 FC = +2.712, t-test p < 0.001).
This table shows molecular features associated with PIMREG in patient tissues and cancer cell lines. In patient samples, PIMREG shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PIMREG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
